TMCnet News
Global Tetanus Therapeutics Report 2016: Pipeline Review of 17 Companies & 35 Drug Molecules - Research and MarketsResearch and Markets has announced the addition of the "Tetanus - Pipeline Review, H2 2016" report to their offering. Tetanus pipeline therapeutics constitutes close to 38 molecules, out of which approximately 35 molecules are developed by Companies and the remaining by Universities and Institutes. Our latest report, Tetanus - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, INDCTA Filed, Preclinical and Discovery stages are 2, 1, 11, 1, 5, 1, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively. Furthermore, this report also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/x449hv/tetanus
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006356/en/ |
